Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens
Autore:
Nordoy, T; Kolstad, A; Tuck, MK; Aaberge, IS; Husebekk, A; Kaminski, MS;
Indirizzi:
Univ Tromso Hosp, Dept Oncol, N-9038 Tromso, Norway Univ Tromso Hosp Tromso Norway N-9038 Dept Oncol, N-9038 Tromso, Norway Univ Tromso Hosp, Dept Immunol & Transfus Med, N-9038 Tromso, Norway Univ Tromso Hosp Tromso Norway N-9038 ransfus Med, N-9038 Tromso, Norway Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Ann Arbor, MI 48109USA Univ Michigan Ann Arbor MI USA 48109 prehens Canc, Ann Arbor, MI 48109USA Natl Inst Publ Hlth, Dept Vaccinol, Oslo, Norway Natl Inst Publ Hlth Oslo Norway Publ Hlth, Dept Vaccinol, Oslo, Norway
Titolo Testata:
CLINICAL IMMUNOLOGY
fascicolo: 1, volume: 100, anno: 2001,
pagine: 40 - 48
SICI:
1521-6616(200107)100:1<40:RWITIP>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; I-131 TOSITUMOMAB; ANTIBODY; MUMPS; COMPARTMENT; MEASLES; RUBELLA; MEMORY;
Keywords:
radioimmunotherapy; B-cell lymphoma; humoral immunity; anti-CD20; iodine-131 tositumomab;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Nordoy, T Univ Tromso Hosp, Dept Oncol, N-9038 Tromso, Norway Univ Tromso Hosp Tromso Norway N-9038 l, N-9038 Tromso, Norway
Citazione:
T. Nordoy et al., "Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens", CLIN IMMUNO, 100(1), 2001, pp. 40-48

Abstract

Thirty-one previously untreated patients with follicular low-grade B-cell non-Hodgkin's lymphoma expressing the CD20 antigen were treated with iodine-131 tositumomab therapy between 1996 and 1998. The therapy led to a temporary depletion of peripheral blood B-lymphocytes. Recovery of B-cells occurred in most cases by 3 to 6 months and in all patients by 12 months posttherapy. A temporary decline in T-cell subpopulations, but no reduction in serum immunoglobulin levels, could be observed. ELISA techniques were used to detect specific antibodies against rubella, mumps, varicella tester, measles, and tetanus. Almost all patients remained seropositive against the different antigens during the 1- to a-year follow-up. No significant reduction inantibody concentrations to tetanus or measles could be detected. The data show that acquired humoral immunity against common antigens appears to be preserved despite a temporary loss of B-lymphocytes. (C) 2001 Academic Press.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 06:55:05